TWiV 921: COVID-19 clinical update #124 with Dr. Daniel Griffin

July 23, 2022

In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC’s recommendation of Novavax’s COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.

Click arrow to play
Download TWiV 921 (24 MB .mp3, 41 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *

3 comments on “TWiV 921: COVID-19 clinical update #124 with Dr. Daniel Griffin

  1. Stephen Vail Jul 23, 2022

    Now that the FDA has authorized pharmacists to prescribe and dispense Paxlovid, how does one find a pharmacy that will do it? I have asked some of my local pharmacies about this (including CVS), and they all say “we do not follow that protocol”.

  2. Robin Owen Jul 24, 2022

    I got Evusheld in February 2022. It is supposed to provide protection for six months, and it has been that. My rheumatologist said there is no recommendation to administer it again. Are there studies to show that it is still effective beyond six months? What is the thinking on additional doses for immunosuppressed people? Thank you!